ENTRY       D10741                      Drug
NAME        Idarucizumab (USAN/INN);
            Idarucizumab (genetical recombination) (JAN);
            Praxbind (TN)
PRODUCT     PRAXBIND (Boehringer Ingelheim Pharmaceuticals)
SEQUENCE    (Heavy chain)
            QVQLQESGPG LVKPSETLSL TCTVSGFSLT SYIVDWIRQP PGKGLEWIGV IWAGGSTGYN
            SALRSRVSIT KDTSKNQFSL KLSSVTAADT AVYYCASAAY YSYYNYDGFA YWGQGTLVTV
            SSASTKGPSV FPLAPSSKST SGGTAALGCL VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ
            SSGLYSLSSV VTVPSSSLGT QTYICNVNHK PSNTKVDKKV EPKSC
            (Light chain)
            DVVMTQSPLS LPVTLGQPAS ISCKSSQSLL YTDGKTYLYW FLQRPGQSPR RLIYLVSKLD
            SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCLQSTHFP HTFGGGTKVE IKRTVAAPSV
            FIFPPSDEQL KSGTASVVCL LNNFYPREAK VQWKVDNALQ SGNSQESVTE QDSKDSTYSL
            SSTLTLSKAD YEKHKVYACE VTHQGLSSPV TKSFNRGEC
            (Disulfide bridge: H22-H95, H149-H205, H225-L-219, L23-L93, L139-L199)
  TYPE      Peptide
REMARK      Therapeutic category: 3399
            ATC code: V03AB37
            Product: D10741<JP/US>
EFFICACY    Neutralizer (dabigatran)
  TYPE      Monoclonal antibody
COMMENT     Reversal of anticoagulant effects of dabigatran [DR:D07082]
TARGET      Dabigatran [DR:D07082] [DG:DG00164]
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             V VARIOUS
              V03 ALL OTHER THERAPEUTIC PRODUCTS
               V03A ALL OTHER THERAPEUTIC PRODUCTS
                V03AB Antidotes
                 V03AB37 Idarucizumab
                  D10741  Idarucizumab (USAN/INN) &lt;JP/US&gt;
            Therapeutic category of drugs in Japan [BR:br08301]
             3  Agents affecting metabolism
              33  Blood and body fluid agents
               339  Miscellaneous
                3399  Others
                 D10741  Idarucizumab (USAN/INN); Idarucizumab (genetical recombination) (JAN)
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D10741
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10741
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D10741
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D10741
DBLINKS     CAS: 1362509-93-0
            PubChem: 254741702
///
